Flood P, Yamauchi K, Gershon R K
J Exp Med. 1982 Aug 1;156(2):361-71. doi: 10.1084/jem.156.2.361.
We described a T suppressor factor made by an I-J- Ly-2 T cell (Ly-2 TsF) that expresses biological activity only when its acceptor cell shares H-2-linked polymorphic genes with the cells that made the Ly-2 TsF (or when the producer cell had differentiated in a thymic environment where the gene products of the acceptor cell were expressed). The Ly-2 TsF requires the presence of I-J+ Ly-1 cells in the assay culture to express its suppressive activity, although removal of the I-J+ Ly-1 cells in the assay cultures with an I-J+ soluble factor derived from them. This I-J+ molecule not only fails to bind antigen but is also antigen nonspecific in that it can come from Ly-1 cells making factors of irrelevant specificities. For the I-J+ molecule to replace the activity of the I-J+ Ly-1 cell in the assay population, in restoring suppressive function in cultures depleted of I-J+ Ly-1 cells, it must share genetic polymorphisms linked to the I-J subregion with the Ly-2 TsF and genetic polymorphisms linked to Igh-V with the target cell. These results indicate that an I-J+ antigen-nonspecific molecule combines with an antigen-specific Ly-2 TsF via an I-J- anti-I-J "type" of interaction. The resultant molecular complex is focused on a cell surface receptor of the acceptor cell. This focusing event is controlled by the antigen-nonspecific I-J+ molecule, and the precise interaction with the receptor on the acceptor cell is controlled by Igh-V-linked polymorphic gene products. The antigenic specificity of the interaction is controlled by a receptor for antigen on the I-J- component of the complex. Thus, three focusing events are required for Ly-2 TsF to express biologic activity: (a) the Ly-2 TsF must be focused on an acceptor cell that has the same antigenic specificity (most likely via an antigen bridge); (b) it must also be focused onto an I-J+ antigen-nonspecific molecule that we refer to as a "schlepper" molecule (most likely via an I-J anti-I-J bridge); and (c) the schlepper molecule must focus the molecular complex on an Igh-V-controlled receptor on the antigen-specific target cell.
我们描述了一种由I-J-Ly-2 T细胞产生的T抑制因子(Ly-2 TsF),只有当其受体细胞与产生Ly-2 TsF的细胞共享H-2连锁多态基因时(或者当产生细胞在表达受体细胞基因产物的胸腺环境中分化时),它才会表达生物活性。Ly-2 TsF在检测培养物中需要有I-J+ Ly-1细胞才能表达其抑制活性,尽管可用源自它们的I-J+可溶性因子去除检测培养物中的I-J+ Ly-1细胞。这种I-J+分子不仅不能结合抗原,而且在抗原方面是非特异性的,因为它可以来自产生无关特异性因子的Ly-1细胞。为了使I-J+分子在检测群体中替代I-J+ Ly-1细胞的活性,即在耗尽I-J+ Ly-1细胞的培养物中恢复抑制功能,它必须与Ly-2 TsF共享与I-J亚区连锁的遗传多态性,并与靶细胞共享与Igh-V连锁的遗传多态性。这些结果表明,一种I-J+抗原非特异性分子通过I-J-抗I-J“类型”的相互作用与抗原特异性Ly-2 TsF结合。所得的分子复合物聚焦于受体细胞的细胞表面受体。这种聚焦事件由抗原非特异性I-J+分子控制,与受体细胞上受体的精确相互作用由Igh-V连锁的多态基因产物控制。复合物I-J-成分上的抗原受体控制相互作用的抗原特异性。因此,Ly-2 TsF表达生物活性需要三个聚焦事件:(a)Ly-2 TsF必须聚焦于具有相同抗原特异性的受体细胞(最有可能通过抗原桥);(b)它还必须聚焦于我们称为“转运”分子的I-J+抗原非特异性分子上(最有可能通过I-J抗I-J桥);(c)转运分子必须将分子复合物聚焦于抗原特异性靶细胞上由Igh-V控制的受体上。